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ABSTRACT
Recommendation 1
Management of patients with glioblastoma multi-
forme (GBM) should be highly individualized and
should take a multidisciplinary approach involving
neuro-oncology, neurosurgery, radiation oncology,
and pathology, to optimize treatment outcomes. Pa-
tients and caregivers should be kept informed of the
progress of treatment at every stage.
Recommendation 2
Sufficient tissue should be obtained during surgery
for cytogenetic analysis and, whenever feasible, for
tumour banking.
Recommendation 3
Surgery is an integral part of the treatment plan, to
establish a histopathologic diagnosis and to achieve
safe, maximal, and feasible tumour resection, which
may improve clinical signs and symptoms.
Recommendation 4
The preoperative imaging modality of choice is mag-
netic resonance imaging (MRI) with gadolinium as the
contrast agent. Other imaging modalities, such as
positron emission tomography with [18F]-fluoro-
deoxy-D-glucose, may also be considered in selected
cases. Postoperative imaging (MRI or computed to-
mography) is recommended within 72 hours of sur-
gery to evaluate the extent of resection.
Recommendation 5
Postoperative external-beam radiotherapy is recom-
mended as standard therapy for patients with GBM.
The recommended dose is 60 Gy in 2-Gy fractions.
The recommended clinical target volume should be
identified with gadolinium-enhanced T1-weighted
MRI, with a margin in the order of 2–3 cm. Target
volumes should be determined based on a postsurgi-
cal planning MRI. A shorter course of radiation may
be considered for older patients with poor perfor-
mance status.
Recommendation 6
During RT, temozolomide 75 mg/m2 should be admin-
istered concurrently for the full duration of radio-
therapy, typically 42 days. Temozolomide should be
given approximately 1 hour before radiation therapy,
and at the same time on the days that no radiotherapy
is scheduled.
Recommendation 7
Adjuvant temozolomide 150 mg/m2, in a 5/28-day
schedule, is recommended for cycle 1, followed by
5 cycles if well tolerated. Additional cycles may be
considered in partial responders. The dose should be
increased to 200 mg/m2 at cycle 2 if well tolerated.
Weekly monitoring of blood count is advised during
chemoradiation therapy in patients with a low white
blood cell count. Pneumocystis carinii pneumonia has
been reported, and prophylaxis should be considered.
Recommendation 8
For patients with stable clinical symptoms during
combined radiotherapy and temozolomide, comple-
tion of 3 cycles of adjuvant therapy is generally ad-
vised before a decision is made about whether to
continue treatment, because pseudo-progression is a
common phenomenon during this time. The recom-
mended duration of therapy is 6 months. A longer
duration may be considered in patients who show
continuous improvement on therapy.
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Recommendation 9
Selected patients with recurrent GBM may be candi-
dates for repeat resection when the situation appears
favourable based on an assessment of individual pa-
tient factors such as medical history, functional sta-
tus, and location of the tumour. Entry into a clinical
trial is recommended for patients with recurrent
disease.
Recommendation 10
The optimal chemotherapeutic strategy for patients
who progress following concurrent chemoradiation
has not been determined. Therapeutic and clinical–
molecular studies with quality of life outcomes are
needed.
KEY WORDS
Brain tumour, glioblastoma, radiotherapy, chemo-
therapy, temozolomide
1. INTRODUCTION
Glioblastoma multiforme (GBM) is a World Health
Organization grade IV astrocytoma and the most com-
mon and aggressive primary brain tumour 1. In North
America, the estimated age-adjusted incidence of GBM
is 3.0 per 100,000 population 1. It occurs more com-
monly in males (male:female ratio of approximately
3:2) and is typically diagnosed in patients in their
sixth or seventh decade.
The preoperative imaging modality of choice is
gadolinium-enhanced magnetic resonance imaging
(MRI). Although contrast-enhanced MRI may indicate
a discrete border, GBM tumours are characterized by
extensive microvascular infiltration and rapid prolif-
eration. Based on distinct pathogenetic features, at
least two subtypes of GBM can be defined. Primary
(de novo) glioblastoma is more common in older pa-
tients (mean age: 55 years) 2 and typically harbours
overexpression or mutation of epidermal growth fac-
tor receptor, genetic losses on chromosome 10, p16
or p19 alterations, or loss of the tumour suppressor
protein phosphatase and tensin homologue 3–6. Sec-
ondary glioblastoma develops more slowly from a
lower-grade tumour and typically occurs in younger
patients (£45 years). Genetic alterations may include
TP53 mutation or overexpression of platelet-derived
growth factor receptor a 7.
Although imaging techniques and multimodal
treatment strategies have improved since the mid-
1980s, little impact has been made on the ultimate
prognosis of GBM. A population-based cohort study
of all Ontario Cancer Registry cases of GBM identi-
fied between 1982 and 1994 found that the median
survival of patients receiving radiotherapy (RT) and
surgery was 11 months; median survival with sur-
gery alone was 3 months 8. An analysis of the Al-
berta Cancer Registry database of GBM patients diag-
nosed between 1975 and 1991 reported that only 1.8%
survived at least 3 years 9. A decade later, an analy-
sis by the Glioma Outcomes Project of cases diag-
nosed between 1997 and 2001 reported a median
survival of 40.9 weeks for newly-diagnosed patients
with GBM 10. An analysis of the Surveillance, Epide-
miology, and End Results database found no signifi-
cant improvement in the GBM survival rate after the
1980s 1.
The principal reasons for poor outcome in GBM
are the high rates of recurrence and of resistance to
chemotherapy. Choucair et al. estimated that more
than 90% of gliomas recur, typically at the site of the
original tumour 11. Numerous chemotherapy regi-
mens, administered either before RT or adjuvantly,
have been investigated, but they have had little im-
pact on patient outcomes 12–16. Prognosis is affected
by the histologic features of the tumour, patient age,
and performance status 17,18.
Standard treatment for GBM was significantly al-
tered following the results of a large phase III trial
conducted by the European Organization for the Re-
search and Treatment of Cancer (EORTC) and the Na-
tional Cancer Institute of Canada 19. The EORTC–NCIC
CE3 trial randomized 573 newly-diagnosed glioblas-
toma patients to RT alone (2 Gy, 5/7-day schedule for
6 weeks, 60 Gy total), or to RT in combination with
the oral alkylating agent temozolomide. The temo-
zolomide dose was 75 mg/m2 daily during RT, fol-
lowed by adjuvant temozolomide 150–200 mg/m2
daily in a 5/28-day schedule for 6 cycles. With the
RT–temozolomide combination, 2-year survival was
26.5% as compared with 10.4% with RT alone. Me-
dian survival was 12.1 months and 14.6 months re-
spectively. As a result, concurrent RT and
temozolomide, followed by 6 monthly cycles of ad-
juvant temozolomide, became the new standard of
care for patients newly diagnosed with GBM.
However, numerous questions remain about how
to identify patients who will be more likely to respond
to treatment and how to optimize a multimodal ap-
proach to patient management. The recommendations
that follow were developed by a multidisciplinary
panel of Canadian neuro-oncologists, neurosurgeons,
and radiation oncologists—based on level 1 evidence
where possible—as a guide to optimizing the man-
agement of patients with GBM.
2. THE RECOMMENDATIONS
2.1 General Principles
Recommendation 1 Management of patients with
GBM should be highly individualized and should take
a multidisciplinary approach involving neuro-oncol-
ogy, neurosurgery, radiation oncology, and pathol-
ogy, to optimize treatment outcomes. The care path
of GBM is complex and requires the cooperation andCURRENT ONCOLOGY—VOLUME 14, NUMBER 3
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integration of services from multiple health care spe-
cialties and institutions so as to avoid unacceptable
wait times.
All surgeries should be presented at a weekly
brain tumour conference, with the neurosurgeon, ra-
diation oncologist, and neuro-oncologist present. Ide-
ally, for each case, the multidisciplinary team should
review the patient’s clinical status, neuroimaging, and
histopathologic findings to determine the optimal
treatment approach.
It is recommended that the neurosurgeon inform
the patient of the diagnosis. Patients and caregivers
should be kept informed of the progress of treatment
at every stage. Patients should receive a brain tumour
information package to help them understand GBM and
the treatment options, and to better inform their deci-
sion-making. Patient consent should be obtained for
tumour banking.
2.2 Pathology
Specific, unique genetic changes are common in as-
trocytic tumours. An estimated one half of grades II–
III infiltrating astrocytomas have detectable mutations
in the TP53 tumour suppressor gene 20. Loss of het-
erozygosity on chromosomes 1p and 19q is usually
associated with oligodendroglioma, but sometimes
occurs in oligoastrocytomas. Loss of heterozygosity
is associated with increased sensitivity to pro-
carbazine–lomustine–vincristine chemotherapy 21. In
that regard, two EORTC phase II trials reported that first-
or second-line temozolomide produced a high re-
sponse rate in patients with recurrent or progressive
oligoastrocytoma or oligodendroglioma 22,23; re-
sponse was associated with 1p and 19q loss 24. Glio-
blastoma multiforme is more chemoresistant, and
genetic markers do not appear to have comparable
prognostic significance 25. Of particular importance,
however, is O6-methylguanine DNA methyltransferase
(MGMT), a repair protein that removes methyl adducts
and transfers them to an internal cysteine residue 26.
Because the O6 position is one of the targets of alky-
lating chemotherapeutic agents, MGMT activity en-
hances tumour resistance by repairing cytoxic
damage. Conversely, tumour sensitivity is enhanced
if MGMT is silenced through hypermethylation of the
CpG islands in the promoter region 27–29.
A number of studies have indicated that MGMT
promoter methylation is predictive of a good response
to alkylating agents such as 1,3-bis(2-chloroethyl)-
1-nitrosourea (BCNU) and cyclophosphamide 30,31.
Following the phase III study of combined RT and tem-
ozolomide 19, Hegi et al. analyzed the MGMT promoter
methylation status of 206 evaluable patients 32. In
92 tumours (44.7%), MGMT promoter methylation was
detectable. Median survival was 18.2 months in pa-
tients with promoter methylation as compared with
12.2 months in those without methylation, and me-
dian survival was 21.7 months in RT–temozolomide-
treated patients with promoter methylation. In the
subgroup of patients with promoter methylation,
2-year survival was 46% in the RT–temozolomide
group as compared with 22.7% in patients treated
with RT alone (Table I). In the subgroup of patients
without promoter methylation, median survival was
only marginally superior with combined RT–temozol-
omide than with RT alone (12.7 months vs.
11.8 months); 2-year survival was 13.8% as compared
with <2% respectively.
Temozolomide is a recommended treatment for
newly-diagnosed GBM and for recurrent high-grade
gliomas. Although MGMT methylation status appears
to be a prognostic factor for increased survival and
possibly for better response to temozolomide, a pro-
spective study is required before promoter hyper-
methylation can be used as a guide to treatment
decisions in GBM.
Recommendation 2 The molecular genetic determi-
nation of brain tumours is becoming increasingly
important, enabling more accurate diagnosis and
prognosis. Sufficient tissue should be obtained dur-
ing surgery for cytogenetic analysis and, whenever
feasible, for tumour banking. The preliminary pathol-
ogy report should be available within 48 hours post
surgery; the final report should be completed within
8 working days post surgery.
2.3 Surgery
Recommendation 3 Surgery is an integral part of the
treatment plan, to establish a histopathologic diag-
nosis and to achieve safe maximal tumour resection,
which may improve clinical signs and symptoms.
A gross total resection, if achievable, is advised
in any patients with a primary or recurrent malignant
glial tumour if the surgery can be performed without
significant risk to the patient. Simpson et al. analysed
data from 645 GBM patients in three prospective Ra-
diation Therapy Oncology Group trials 33. Surgery
consisted of total resection (19%), partial resection
(64%), or biopsy only (17%). Median survival was
TABLE  I Effect of methylation status of methylguanine DNA
methyltransferase (MGMT) promoter on progression-free survival
(PFS) and overall survival (OS) in patients receiving radiotherapy
plus temozolomide (TMZ) versus radiotherapy (RT) alone a
Clinical endpoint TMZ + RT RT
(n=106) (n=100)
Methylated MGMT (n)4 6 4 6
6-Month PFS 47.8 68.9
2-Year OS 22.7 46.0
Unmethylated MGMT (n)5 4 6 0
6-Month PFS 35.2 40.0
2-Year OS <2 13.8
a Adapted from reference 32.MASON et al.
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11.3 months for total resection, 10.4 months for par-
tial resection, and 6.6 months for biopsy.
Recommendation 4 The preoperative imaging mo-
dality of choice is MRI with gadolinium as the con-
trast agent. Other imaging modalities, such as positron
emission tomography with [18F]-fluoro-deoxy-D-glu-
cose, may also be considered in selected cases 34.
Postoperative imaging (MRI or computed tomography)
is recommended within 72 hours of surgery to evalu-
ate the extent of resection.
2.4 Radiotherapy
The use of adjuvant external-beam RT is well estab-
lished in the postoperative treatment of GBM. A pooled
analysis of six randomized trials by Cancer Care
Ontario reported a significant survival benefit
favouring postoperative RT as compared with no RT
(risk ratio: 0.81) 35,36. Overall, median survival is
approximately 36–48 weeks with adjuvant RT as com-
pared with 14–22 weeks with surgery alone 37–39.
External-beam RT is generally administered over
5–6 weeks, delivering a total dose of 50–60 Gy in
1.8- to 2.0-Gy fractions 40. Doses above 60 Gy and
boost RT do not appear to influence survival 40,41.
Alternative forms of fractionation have been in-
vestigated. Accelerated fractionation delivers stan-
dard fraction sizes more frequently (for example, 2
or 3 times daily) to reduce the overall treatment
time. Several studies have reported no increased sur-
vival, although no increased toxicity was
found 42–44. This approach may be an option for se-
lected patients (such as the elderly), but additional
study is needed.
Hyperfractionation, which delivers a higher total
radiation dose in a larger number of smaller fractions,
showed no improvement in time to tumour progres-
sion or survival 45,46.
Radiotherapy should be initiated within 4 weeks
of surgery.
Recommendation 5 Postoperative external-beam RT
is recommended as standard therapy for patients with
GBM. The recommended dose is 60 Gy in 2-Gy frac-
tions 35,36. The recommended clinical target volume
should be identified with gadolinium-enhanced
T1-weighted MRI, with a margin in the order of 2–
3 cm, given that most recurrences will occur within
a few centimetres of the tumour mass 47,48. Target
volumes should be determined based on a postsurgi-
cal planning MRI. A shorter course of radiation may
be considered for older patients with poor perfor-
mance status 49,50.
2.5 Chemotherapy
Glioblastoma multiforme has been viewed as a
chemoresistant tumour, and the nitrosoureas, the tra-
ditional mainstays of treatment, have had modest ef-
ficacy, but are associated with significant toxicity 39.
Most studies were reported decades ago, but a recent
phase II trial evaluated BCNU 80 mg/m2 on days 1–3
every 8 weeks (maximum 6 cycles) in 40 patients
with recurrent GBM who had undergone surgery and
RT 51. The median time to progression was 13 weeks;
the 6-month progression-free survival (PFS) was
17.5%. Significant side effects included reversible
hematologic toxicities and chronic hepatic and pul-
monary toxicity.
Recommendation 6 During RT, temozolomide
75 mg/m2 should be administered concurrently for
42 days 35. Temozolomide should be given approxi-
mately 1 hour before RT, and at the same time on the
days when no RT is scheduled (weekends).
Whether the clinical benefit of this combination
is attributable in part to the radiosensitizing effects
of temozolomide is unclear. To date, four in vitro stud-
ies have suggested a radiosensitizing effect with tem-
ozolomide for some cancer cell lines 52–55, but
additional research is needed.
Recommendation 7 Adjuvant temozolomide
150 mg/m 2, in 5/28-day schedule, is recommended
for cycle 1, followed by 5 cycles if well tolerated.
Additional cycles may be considered in partial re-
sponders or in those with continuing radiologic im-
provement. The dose should be increased to
200 mg/m2 at cycle 2 if well tolerated. Weekly moni-
toring of blood count is advised during chemoradi-
ation therapy in patients with a low white blood cell
count. Pneumocystis carinii pneumonia has been re-
ported, and prophylaxis should be considered 56.
Recommendation 8 For patients with stable clinical
symptoms during RT–temozolomide, completion of
3 cycles of adjuvant therapy is generally advised be-
fore a decision is made about whether to continue
treatment. In the first few weeks or months follow-
ing completion of RT, MRI is not reliable to assess true
progression. Evidence of progression outside the RT
field is indicative of true progression. A longer dura-
tion may be considered in patients who show con-
tinuous improvement on therapy.
2.6 Recurrent GBM
Recommendation 9 Selected patients with recurrent
GBM may be candidates for repeat resection when the
situation appears favourable based on an assessment
of individual patient factors such as medical history,
functional status, and location of the tumour 57,58.
Entry into a clinical trial is recommended for patients
with recurrent disease.
Recommendation 10 The optimal chemotherapeu-
tic strategy for patients who progress following
concurrent chemoradiation has not been determined.
Therapeutic and clinical-molecular studies with qual-
ity of life outcomes are needed 35.CURRENT ONCOLOGY—VOLUME 14, NUMBER 3
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For patients not receiving chemotherapy at the
time of progression, re-challenge with temozolomide
to deplete MGMT might be attempted, but clinical data
on this strategy are lacking.
Some preliminary data suggest that novel dose-
intense schedules may provide some benefit. Khan
et al. reported a 6-month PFS of 19% with temozolo-
mide 75 mg/m2 in a 42/70-day schedule 59. In a small
phase II study by Wick et al., the 6-month PFS was
48% with temozolomide 150 mg/m2 administered in
a 7-day on / 7-day off schedule 60. Although the find-
ings are promising, additional phase II studies are re-
quired before the foregoing dosing regimens can be
recommended.
A number of chemotherapeutic agents, includ-
ing nitrosoureas, carboplatin, etoposide, irinotecan,
and imatinib 61–64, have been used as salvage therapy
either alone or in combination. Additional trials with
a variety of agents are underway, but preliminary re-
sults from single-agent studies have been disappoint-
ing. Table II summarizes phase II studies in GBM.
For patients who progress on temozolomide, com-
bination therapy may be possible; several recent trials
have evaluated various temozolomide combinations
(Table II). For example, the efficacy of bolus temo-
zolomide 130 mg/m2 followed by 70 mg/m2 every
12 hours for 5 days, plus cisplatin 75 mg/m 2, was
evaluated in 50 patients with recurrent GBM 65. Among
the 49 evaluable patients, 1 patient achieved a com-
plete response, and 9 achieved partial responses. The
6-month PFS was 34%; the 12-month PFS was 4%.
Overall survival was 11.2 months. The most common
grade 3–4 toxicity was granulocytopenia, which oc-
curred in 8% of cycles.
3. CONCLUSIONS
Surgery followed by RT still represents the primary
approach to the treatment of GBM. The addition of
temozolomide chemotherapy to the standard of care
has significantly increased the proportion of patients
who survive more than 2 years. However, additional
progress still needs to be made, because almost one
half of GBM patients will not survive the first year
after surgery. Additional research is needed to build
on recent clinical gains and to focus on new drug
combinations or therapies that could potentially fur-
ther improve outcomes in patients with GBM.
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